{"id":"NCT03688711","sponsor":"Zealand Pharma","briefTitle":"Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM","officialTitle":"A Randomized, Double-blind, Parallel-group Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus (T1DM) Compared to Placebo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-01","primaryCompletion":"2019-03-11","completion":"2019-03-11","firstPosted":"2018-09-28","resultsPosted":"2021-05-19","lastUpdate":"2021-05-19"},"enrollment":45,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypoglycemia","Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"Dasiglucagon","otherNames":["ZP4207"]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo for dasiglucagon"]}],"arms":[{"label":"Dasiglucagon","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo","primaryOutcome":{"measure":"Time to Plasma Glucose Recovery.","timeFrame":"0-45 minutes after dosing","effectByArm":[{"arm":"Dasiglucagon 0.6 mg","deltaMin":10,"sd":null},{"arm":"Placebo","deltaMin":35,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":["Nausea","Vomiting","Hypoglycemia","Headache","Diarrhea"]}}